Intracavitary administration of OK-432 with subcutaneous priming for malignant ascites in a case of advanced renal cell carcinoma

被引：3

作者：

Kageyama, Y ^{[1
]}

Sakai, Y ^{[1
]}

Arai, G ^{[1
]}

Hyochi, N ^{[1
]}

Suzuki, M ^{[1
]}

Masuda, H ^{[1
]}

Kawakami, S ^{[1
]}

Hayashi, T ^{[1
]}

Okuno, T ^{[1
]}

Kobayashi, T ^{[1
]}

Kihara, K ^{[1
]}

机构：

[1] Tokyo Med & Dent Univ, Grad Sch, Dept Urol & Reprod Med, Bunkyo Ku, Tokyo 1138519, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2002年 / 9卷 / 01期

关键词：

ascites; cancer; kidney; OK-432;

D O I：

10.1046/j.1442-2042.2002.00411.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The intracavitary injection of OK-432 (a streptococcal preparation) with subcutaneous priming has been shown to be an effective immunotherapy for patients with malignant effusion. We applied this treatment in a case of advanced renal cell carcinoma with massive ascites. The patient received 0.2 Klinishe Einheit (KE) OK-432 in the subcutaneous injection twice (day 1 and day 7) followed by 10KE OK-432 intra-abdominal administration (day 9). The treatment was performed safely without major side-effects except for transient pyrexia. A significant reduction of ascites was noted 1 month after the treatment without subsequent re-accumulation. Intracavitary injection of OK-432 with subcutaneous priming seems to be a simple, safe and effective treatment for ascites in advanced renal cell carcinoma.

引用

页码：57 / 59

页数：3

共 18 条

[1] NEUTROPHIL-MEDIATED TUMOR-CELL DESTRUCTION IN CANCER ASCITES .2. A OK-432 ATTRACTS KILLER NEUTROPHILS THROUGH ACTIVATION OF COMPLEMENT-C5 [J].

FUJIMURA, T ;

TORISU, M .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1987, 43 (02) :174-184

[2]

HAYASHI Y, 1990, SURGERY, V107, P74

[3]

KAGEYAMA Y, 1996, BIOTHERAPY, V10, P1221

[4]

Katano M, 1998, ANTICANCER RES, V18, P3917

[5]

KATANO M, 1983, SURGERY, V93, P365

[6]

KATANO M, 1982, CANCER, V50, P62, DOI 10.1002/1097-0142(19820701)50:1<62::AID-CNCR2820500113>3.0.CO

[7]

2-0

[8] Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: Role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo [J].

Kitsuki, H ;

Katano, M ;

Ikubo, A ;

Morisaki, T ;

Anann, K ;

Tanaka, M ;

Torisu, M .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 78 (03) :283-290

[9] OK-432-INDUCED ENHANCEMENT OF ICAM-1 EXPRESSION ON TUMOR-CELLS POSITIVELY CORRELATES TO THERAPEUTIC EFFECTS FOR MALIGNANT EFFUSION [J].

KITSUKI, H ;

UCHIYAMA, A ;

YOSHIDA, T ;

TORISU, M .

CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 71 (01) :89-95

[10] TREATMENT OF CANCER ASCITES BY INTRAPERITONEAL ADMINISTRATION OF A STREPTOCOCCAL PREPARATION OK-432 WITH FRESH HUMAN-COMPLEMENT - ROLE OF COMPLEMENT-DERIVED CHEMOTACTIC FACTOR TO NEUTROPHILS [J].

KONDO, M ;

KATO, H ;

YOSHIKAWA, T ;

SUGINO, S .

INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (07) :715-+

← 1 2 →